|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 重组脊髓灰质炎病毒用于治疗复发胶质母细胞瘤(英文)显示文摘Background The prognosis of patients with recurrent World Health Organization(WHO)grade IV malignant glioma is dismal,and there is currently no effective therapy.We conducted a dose-finding and toxicity study in this population of patients,evaluating convection-enhanced,intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera(PVSRIPO).PVSRIPO recognizes the poliovirus receptor CD155,which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment.Methods We enrolled consecutive adult patients who had recurrent supratentorial WHO grade IV malignant glioma,confirmed on histopathological testing,with measurable disease(contrast-enhancing tumor of≥1 cm and≤5.5 cm in the greatest dimension).The study evaluated seven doses,ranging between 107 and 1010 50%tissue-culture infectious doses(TCID50),first in a dose-escalation phase and then in a dose-expansion phase.Results From May 2012 through May 2017,a total of 61 patients were enrolled and received a dose of PVSRIPO.Dose level-1(5.0×107TCID50)was identified as the phase 2 dose.One dose-limiting toxic effect was observed;a patient in whom dose level 5(1010TCID50)was administered had a grade 4 intracranial hemorrhage immediately after the catheter was removed.To mitigate locoregional inflammation of the infused tumor with prolonged glucocorticoid use,dose level 5 was deescalated to reach the phase 2 dose.In the dose-expansion phase,19%of the patients had a PVSRIPO-related adverse event of grade 3 or higher.Overall survival among the patients who received PVSRIPO reached a plateau of 21%(95%confidence interval,11 to 33)at 24 months that was sustained at 36 months.Conclusions Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential.The survival rate among patients who receivedPVSRIPO immunotherapy was higher at 24 and 36 months than the rate among historical controls. | Desjardins A Gromeier M Herndon JE 2nd Beaubier N Bolognesi DP Friedman AH Friedman HS McSherry F Muscat AM Nair S Peters KB Randazzo D Sampson JH Vlahovic G Harrison WT McLendon RE Ashley D Bigner DD | 2018 | 中华神经外科疾病研究杂志2018，17，4： | 2 |
| 2 | L - arginine supplementation in peripheral arterial disease: no benefit and possible harm 显示文摘 | Wilson AM Harada R Nair N | 2007 | Circulation2007，116，2： | 1 |
| 3 | Metformin in the treatment of non-alcoholic steatohepatitis:a pilot open label trial显示文摘 | Nair S Diehl AM Wiseman M | 2004 | Aliment Pharmacol Ther2004，20，： | 1 |
| 4 | Metformin in non-alcoholic steatohepatitis (NA SH): efficacy and safety a preliminary report显示文摘 | Nair S Diem AM Perrillo RP | 2002 | Gastroenterology2002，，： | 1 |
| 5 | Metformin in thetreatment of non-alcoholic steatohepatitis : a pilot open labeltrial显示文摘 | Nair S Diehl AM Wiseman M | 2004 | Aliment Pharmacol Ther2004，20，1： | 1 |
| 6 | Metformin in the treat-ment of non-alcoholic steatohepatitis: a pilot open label trial显示文摘 | Nair S Diehl AM Wiseman M | 2004 | Aliment Pbarmaeol Ther2004，20，： | 1 |
| 7 | Tobacc-specific nitrosamines are present at unusually high levels in the saliva of oral snuff users in Sudan显示文摘 | Idris AM Nair J Friesen M | 1992 | Carcinogenic1992，13，： | 1 |
| 8 | L-arginine supple-mentation in peripheral arterial disease: no benefit andpossible harm显示文摘 | Wilson AM Harada R Nair N | 2007 | Circulation2007，116，2： | 1 |
| 9 | Presponse element binding protein and brain-derived neurotrophic factor:molecules that modulate our mood显示文摘 | Nair A Vaidya VA Cyclic AM | 2006 | J Biosci2006，31，3： | 1 |
| 10 | Metformin in the treatment of non-alcoholic steatohepatitis:a pilot open label trial显示文摘 | Nair S Diehl AM Wiseman M | 2004 | Aliment Pha-rmacol Ther2004，20，1： | 1 |
| 11 | Metfonnin in the treatment of non alcoholic steatohepatitis : a pilot open label trial显示文摘 | Nair S Diehi AM Wiseman M | 2004 | AIiment Pharmacol Ther2004，20，： | 1 |
| 12 | Mefformin in non - alcoholic steatohpatitis(NASH): efficacy and safety: a preliminary report 显示文摘 | Nair S Diehl AM Perrillo R | 2002 | Gastroenterology2002，1222，： | 1 |
| 13 | Structural relationships and cellular tropism of staphylococcal superantigen-like proteins显示文摘 | Alshangiti AM Naylor CE Nair SP | 2004 | Infection and Immunity2004，72，7： | 1 |
| 14 | Structural relationships and cellular tropism of staphylococcal superantigen-like proteins显示文摘 | Alshangiti AM Naylor CE Nair SP | 2004 | Infection and Immunity2004，72，7： | 1 |
| 15 | Melformin in the treatment of non-alcoholic steatohepatitis:a pilot open label trial显示文摘 | Nair S Diehl AM Wiseman M | 2004 | Aliment Pharmacol Ther2004，20，： | 1 |
| 16 | Structure of domain Ⅲ of the blood-stage malaria vaccine candidate,Plasmodium falciparum apical membrane antigen 1 (AMA1)显示文摘 | Hinds MG Coley AM | 2002 | J Mol Biol2002，322，4： | 1 |
| 17 | Pharmacoeconomicsand outcomes research degree-granting PhD programs inthe United States 显示文摘 | Slejko JF Libby AM Nair KV | | Res Social Adm Pharm0，2012，： | 1 |
| 18 | The interaction between staphylococcal superantigen-like proteins and human dendriticcells显示文摘 | Al-Shangiti AM Nair SP Chain BM | 2005 | Clin Exp Immunol2005，140，3： | 1 |
| 19 | Mefformin in the treatment of non- alcoholic steatohepatitis: a pilot open label trial 显示文摘 | Nair S Diehl AM Wiseman M | 2004 | Aliment Pharmacol Ther2004，20，1： | 1 |
| 20 | Metformin in the treatment of non-alcoholic steatohepatitis:a pilot open label trial显示文摘 | Nair S Diehl AM Wiseman M | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员